131 related articles for article (PubMed ID: 29870766)
21. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.
Johansen C; Usher PA; Kjellerup RB; Lundsgaard D; Iversen L; Kragballe K
Br J Dermatol; 2009 Feb; 160(2):319-24. PubMed ID: 19016708
[TBL] [Abstract][Full Text] [Related]
22. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis.
Lapteva M; Mondon K; Möller M; Gurny R; Kalia YN
Mol Pharm; 2014 Sep; 11(9):2989-3001. PubMed ID: 25057896
[TBL] [Abstract][Full Text] [Related]
23. A lipid-polymer hybrid nanoparticle (LPN)-loaded dissolving microneedle patch for promoting hair regrowth by transdermal miR-218 delivery.
Zhao Y; Tian Y; Ye W; Wang X; Huai Y; Huang Q; Chu X; Deng X; Qian A
Biomater Sci; 2022 Dec; 11(1):140-152. PubMed ID: 36385302
[TBL] [Abstract][Full Text] [Related]
24. Importance of microRNAs in Skin Oncogenesis and Their Suitability as Agents and Targets for Topical Therapy.
Gerloff D; Sunderkötter C; Wohlrab J
Skin Pharmacol Physiol; 2020; 33(5):270-279. PubMed ID: 33080592
[TBL] [Abstract][Full Text] [Related]
25. Microemulsions mediated effective delivery of methotrexate hydrogel: more than a tour de force in psoriasis therapeutics.
Amarji B; Garg NK; Singh B; Katare OP
J Drug Target; 2016; 24(2):147-60. PubMed ID: 26204326
[TBL] [Abstract][Full Text] [Related]
26. Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis.
Jain A; Pooladanda V; Bulbake U; Doppalapudi S; Rafeeqi TA; Godugu C; Khan W
Nanomedicine; 2017 Oct; 13(7):2251-2262. PubMed ID: 28647592
[TBL] [Abstract][Full Text] [Related]
27. Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis.
Gabriel D; Mugnier T; Courthion H; Kranidioti K; Karagianni N; Denis MC; Lapteva M; Kalia Y; Möller M; Gurny R
J Control Release; 2016 Nov; 242():16-24. PubMed ID: 27639683
[TBL] [Abstract][Full Text] [Related]
28. Capsaicin-loaded vesicular systems designed for enhancing localized delivery for psoriasis therapy.
Gupta R; Gupta M; Mangal S; Agrawal U; Vyas SP
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):825-34. PubMed ID: 25465045
[TBL] [Abstract][Full Text] [Related]
29. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis.
Otkjaer K; Kragballe K; Funding AT; Clausen JT; Noerby PL; Steiniche T; Iversen L
Br J Dermatol; 2005 Nov; 153(5):911-8. PubMed ID: 16225599
[TBL] [Abstract][Full Text] [Related]
30. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment.
Boakye CHA; Patel K; Doddapaneni R; Bagde A; Marepally S; Singh M
J Control Release; 2017 Jan; 246():120-132. PubMed ID: 27170227
[TBL] [Abstract][Full Text] [Related]
31. Perspectives of Lipid-Based Drug Carrier Systems for Transdermal Delivery.
Pradhan M; Srivastava S; Singh D; Saraf S; Saraf S; Singh MR
Crit Rev Ther Drug Carrier Syst; 2018; 35(4):331-367. PubMed ID: 29972681
[TBL] [Abstract][Full Text] [Related]
32. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2.
Xu N; Brodin P; Wei T; Meisgen F; Eidsmo L; Nagy N; Kemeny L; Ståhle M; Sonkoly E; Pivarcsi A
J Invest Dermatol; 2011 Jul; 131(7):1521-9. PubMed ID: 21412257
[TBL] [Abstract][Full Text] [Related]
33. IL-22-induced miR-122-5p promotes keratinocyte proliferation by targeting Sprouty2.
Jiang M; Ma W; Gao Y; Jia K; Zhang Y; Liu H; Sun Q
Exp Dermatol; 2017 Apr; 26(4):368-374. PubMed ID: 27943426
[TBL] [Abstract][Full Text] [Related]
34. MicroRNAs and potential target interactions in psoriasis.
Zibert JR; Løvendorf MB; Litman T; Olsen J; Kaczkowski B; Skov L
J Dermatol Sci; 2010 Jun; 58(3):177-85. PubMed ID: 20417062
[TBL] [Abstract][Full Text] [Related]
35. Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors.
Katare OP; Raza K; Singh B; Dogra S
Indian J Dermatol Venereol Leprol; 2010; 76(6):612-21. PubMed ID: 21079304
[TBL] [Abstract][Full Text] [Related]
36. MiR-330 inhibits IL-22-induced keratinocyte proliferation through targeting CTNNB1.
Shen H; Zeng B; Wang C; Tang X; Wang H; Liu W; Yang Z
Biomed Pharmacother; 2017 Jul; 91():803-811. PubMed ID: 28501007
[TBL] [Abstract][Full Text] [Related]
37. MiR-20a-3p regulates TGF-β1/Survivin pathway to affect keratinocytes proliferation and apoptosis by targeting SFMBT1 in vitro.
Li R; Qiao M; Zhao X; Yan J; Wang X; Sun Q
Cell Signal; 2018 Sep; 49():95-104. PubMed ID: 29886071
[TBL] [Abstract][Full Text] [Related]
38. The potential of interleukin 12 inhibition in the treatment of psoriasis.
Rosmarin D; Strober BE
J Drugs Dermatol; 2005; 4(3):318-25. PubMed ID: 15898287
[TBL] [Abstract][Full Text] [Related]
39. Enhanced Transdermal Drug Delivery by Sonophoresis and Simultaneous Application of Sonophoresis and Iontophoresis.
Park J; Lee H; Lim GS; Kim N; Kim D; Kim YC
AAPS PharmSciTech; 2019 Jan; 20(3):96. PubMed ID: 30694397
[TBL] [Abstract][Full Text] [Related]
40. Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation.
Ma L; Xue H; Qi R; Wang Y; Yuan L
J Transl Med; 2018 Mar; 16(1):59. PubMed ID: 29523162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
